Factors | Patients n | Median overall survival months | Univariate analysis p-value | Multivariate analysis | |
Hazard ratio (95% CI) | p-value | ||||
Age years | <0.001 | ||||
≤50 | 81 | 20.7 | 1 | ||
51–60 | 117 | 31.5 | 0.66 (0.47–0.92) | 0.015 | |
61–70 | 134 | 26.3 | 0.69 (0.50–0.95) | 0.025 | |
71–80 | 128 | 19.0 | 0.82 (0.59–1.15) | 0.246 | |
>80 | 64 | 14.3 | 0.73 (0.49–1.11) | 0.142 | |
Sex | 0.079 | ||||
Female | 308 | 25.3 | 1 | ||
Male | 216 | 22.4 | 1.25 (0.99–1.57) | 0.065 | |
Smoking history | 0.002 | ||||
Never-smoker | 419 | 25.0 | 1 | ||
Ex-smoker | 52 | 30.3 | 0.96 (0.67–1.37) | 0.801 | |
Current smoker | 53 | 15.4 | 1.66 (1.17–2.36) | 0.005 | |
ECOG PS | <0.001 | ||||
0–1 | 449 | 27.0 | 1 | ||
2–4 | 75 | 11.0 | 2.84 (2.13–3.78) | <0.001 | |
EGFR mutation | 0.060 | ||||
Uncommon | 63 | 19.0 | 1 | ||
Del-19 | 233 | 27.9 | 0.81 (0.59–1.11) | 0.193 | |
L858R | 228 | 23.1 | 0.93 (0.68–1.27) | 0.634 | |
TKI sequence | <0.001 | ||||
First-line | 340 | 19.5 | 1 | ||
Second-line | 117 | 28.0 | 0.70 (0.54–0.91) | 0.007 | |
Third-line or greater | 67 | 34.7 | 0.58 (0.43–0.78) | <0.001 | |
Platinum use | <0.001 | ||||
No | 224 | 15.4 | 1 | ||
Yes | 300 | 30.3 | 0.85 (0.65–1.11) | 0.232 | |
Pemetrexed use | <0.001 | ||||
No | 252 | 15.2 | 1 | ||
Yes | 272 | 32.2 | 0.57 (0.45–0.72) | <0.001 |
ECOG PS: Eastern Cooperative Oncology Group performance status.